of T-dose). Stepwise multivariate Cox regression models revealed fundamental differences in inter-individual effects: hazard ratios for loss of BMI/WC were significantly higher in those subjects with younger age, lower baseline T and higher ratios of delta testosterone over delta estradiol levels induced by treatment (all p<0.01). Advanced age, higher baseline BMI and higher delta estradiol levels resulted in significantly higher hazard ratios for prostate growth/increase in PSA or hematocrit (all p<0.01). Overall, effects were attenuated, but still significant, in subjects with androgen receptor gene CAG repeat length >24, in those with KS or men with non-classical hypogonadism (using non-KS primary hypogonadism as referent, all p<0.05).
INTRODUCTION AND OBJECTIVES: Studies have demonstrated that metabolic syndrome (MetS) is associated with low testosterone (T) levels. However the incremental effect of every MetS component in predicting testosterone deficiency (TD) has not been well explored in the literature. The primary goal of this study was to investigate the association of MetS and low T levels in men from 40 to 80 years of age, while investigating the cumulative effect of the syndrome components METHODS: We reviewed records of all men who presented to our men's health clinic from January 2014 to August 2016. We evaluated age, presence of hypertension, waist circumference (WC), blood glucose level and the serum lipid profile (HDL and triglycerides -TGL), and MetS was considered present when 3 or more factors were present. TD was defined as serum total T <300 ng/dL. Univariable analyses were performed to assess the association variables and T levels. ROC curves analyses were performed to evaluate diagnostic accuracy of each MetS component in predicting TD.
RESULTS: The study comprised 902 men with a mean age of 57.2 AE 9.85 years. The overall prevalence of low T levels was 23.4% and it was similar across all age subgroups: age 40-49 years (y) 22.7%, 50-59y 23.1%, 60-69y 23.8%, and 70-79y 24.4%, p¼0.25. The diagnosis of MetS was established in 27.9% of subjects and was associated with TD (OR¼3. Table 1. CONCLUSIONS: There is an increased prevalence of TD with increasing number of MetS components. WC was the best predictor of TD in our population and age was not associated with lower T levels INTRODUCTION AND OBJECTIVES: PSA secretion is a testosterone (T) dependent process. There is published data suggesting that low serum total T level is an independent predictor of higher stage, higher grade prostate cancer. However, the link between men diagnosed with prostate cancer with low PSA values and T deficiency (TD) has not been explored before.
METHODS: All men diagnosed with prostate cancer since 2000 that had a record of pre-treatment early morning total T level measurement were included in the analysis. We analyzed demographic, clinical and pathological data. Patients were stratified according to pretreatment PSA levels: 0-2; 2.1-4; >4 ng/ml. TD was defined as total T < 300 ng/dL. We evaluated the relationship between these PSA groups and TD. Age, diabetes, and hyperlipidemia were also included in both univariate and multivariable analyses.
RESULTS: Mean age of 349 men was 64AE8 years. The distribution by PSA group was: 5% 0-2, 16% 2.1-4, and 79% >4. The mean T level across the entire cohort was 358AE192 ng/dl. Overall, 38% had a T level < 300 ng/dl; 63% > 300 ng/dl. 9% had diabetes, 10% had hyperlipidemia. The mean T leve by PSA group was: 265AE168 0-2; 328AE210 2.1-4; and 371AE189 >4, p¼0.03. The percentage of men with TD by PSA group was: 53% 0-2; 49% 2.1-4; and 35% >4, p¼0.05. The percentage of men with extremely low T levels (<200) by PSA group was: 35% 0-2; 22% 2.1-4; and 13% >4, p¼0.01. Age, diabetes, and hyperlipidemia were not related to T level grouping on univariate analyses (p¼0.35 to p¼0.81). On multivariable analysis, PSA 0-2 compared to PSA >4: OR¼2.1, 95% CI: 0.82-5.36, p¼0.12; PSA 2.1-4 compared to PSA >4: OR¼1.9, 95% CI: 1.02-3.34, p¼0.04. PSA 0-2 compared to PSA >4 was not significant due to low sample size.
CONCLUSIONS: Low PSA levels predict TD in a cohort of patients with prostate cancer. This finding suggests a possible benefit of adding total T level measurement when a patient with low PSA is diagnosed with prostate cancer.
Source of Funding: None

MP91-10 TESTOSTERONE RECOVERY PROFILES AFTER CESSATION OF ANDROGEN DEPRIVATION THERAPY (ADT)
INTRODUCTION AND OBJECTIVES: It has been demonstrated that the combination use of ADT improves overall and cancerspecific survival in men with unfavorable prostate cancer (PCa). After cessation of ADT, testosterone (T) levels are expected to recover from castrate to normal levels. However, very little is known about T recovery profiles in this population, and many patients remain on castrate levels indefinitely. The aim of this study was to evaluate T recovery after cessation of ADT in PCa patients.
METHODS: We reviewed our prospectively maintained database for PCa patients who received ADT therapy at our institution. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1221
